Skip to main content
What types of page to search?

Popular pages: Undergraduate Postgraduate PhD Accommodation Research International students

Alternatively use our A-Z index.

JIA - Uveitis

Approximately 10-30% of children with JIA develop uveitis, which tends to affect eyes over a long time and mainly involves the front part of the eye. This can lead to visual loss, cataracts, increased pressure, and blindness.

Our stratified workstreams, including Uveitis has made important progress by seeking to explore use of clinical and/or molecular phenotypes associated with disease presentation, stage, outcomes, or treatment responses, to develop and improve individualised care.

In the early stages, there are often no symptoms, and there is currently no way to predict who will develop uveitis. There are a number of treatments for uveitis, including eye drops, immunosuppressive drugs, and steroids. 

The EATC4Children is actively engaged in investigating new treatments for uveitis.

CLUSTER (Childhood Arthritis and associated uveitis: stratification through endotypes and mechanism)

The CLUSTER consortium aims to identify the best way to target the right drug to the right child at the right time in children with JIA and uveitis. The project began in July 2018, and the EATC4Children is leading two of the five workstreams: JIA-uveitis and Industry (Co-CI’s:M. Beresford, A. Ramanan).

 MRC/VA CLUSTER Consortium: We led the JIA-associated uveitis programme and Industry workstream of CLUSTER to enable biomarker identification, differential pathomechanisms and potential targets forchildren responding and not responding to treatments. Having concluded
the formal period of funding of the MRC / VA CLUSTER Consortium during this reporting period (with associated Reports submitted to MRC and VA), we continue to contribute to the legacy of CLUSTER, with bi-annual scientific meetings. Work to explore potential biomarkers to predict
response to treatment in JIA-associated uveitis. Technical issues related to sample numbers, quality and proteomic assays continue to hamper these analyses, and solutions to these challenges are continuing to be sought.

Cluster Logo

Click on the image to be directed to the CLUSTER website.